Development of stealth liposome coencapsulating doxorubicin and fluoxetine

Stealth liposomes form an important subset of liposomes, demonstrating prolonged circulation half-life and improved safety in vivo. Caelyx® (liposomal doxorubicin; Merck & Co., Whitehouse Station, New Jersey, USA) is a successful example of the application of stealth liposomes in anticancer treatment. However, multidrug resistance (MDR) to chemotherapy still remains a critical problem, accounting for more than 90% of treatment failure in patients with advanced cancer. To circumvent MDR, fluoxetine and doxorubicin were tested in combination for synergistic activity in MCF-7 (human breast carcinoma) and MCF-7/adr (doxorubicin-resistant human breast carcinoma) cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell-viability assay. Coencapsulation of doxorubicin and fluoxetine, using an ammonium sulphate gradient, was investigated, and a factorial experiment was designed to determine the optimal drug-to-lipid (D/L) ratio for coencapsulation. Drug release from Dox-Flu-SL (stealth liposome coencapsulating doxorubicin and fluoxetine) under both in vitro and in vivo conditions was determined. In MCF-7 cells, synergism was demonstrated at specific doxorubicin:fluoxetine ratios of between 0.09 and 0.5 (molar ratio), while MCF/7/adr cells demonstrated synergism across all drug ratios. Coencapsulation of doxorubicin and fluoxetine (Dox-Flu-SL) was successfully achieved (optimal doxorubicin:fluoxetine:lipid molar ratio of 0.02:0.05:1), obtaining a mean concentration of 257 ± 12.1 and 513 ± 29.3 µM for doxorubicin and fluoxetine, respectively. Most important, Dox-Flu-SL demonstrated drug release in synergistic ratios in cell-culture media, accounting for the improved cytotoxicity of Dox-Flu-SL over liposomal doxorubicin (LD) in both MCF-7 and MCF-7/adr cells. Pharmacokinetic studies also revealed that Dox-Flu-SL effectively prolonged drug-circulation time and reduced tissue biodistribution. Dox-Flu-SL presents a promising anticancer formulation, capable of effective reversal of drug resistance, and may constitute a novel approach for cancer therapy.

[1]  G. Superti-Furga,et al.  Selective serotonin reuptake inhibitors: a new modality for the treatment of lymphoma/leukaemia? , 2007, Biochemical pharmacology.

[2]  P. Cullis,et al.  Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. , 1998, Biochimica et biophysica acta.

[3]  M. Bally,et al.  Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.

[4]  K. Edwards,et al.  An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[5]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  B. Goh,et al.  Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  L. Mayer,et al.  Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo , 2009, Molecular Cancer Therapeutics.

[8]  M. Stuart,et al.  Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. , 1995, Biochimica et biophysica acta.

[9]  H. Coley.  Mechanisms and consequences of chemotherapy resistance in breast cancer , 2009 .

[10]  K. Edwards,et al.  Formation of transition metal-doxorubicin complexes inside liposomes. , 2002, Biochimica et biophysica acta.

[11]  R. Advani,et al.  A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  M. Bally,et al.  Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. , 2007, Biochimica et biophysica acta.

[14]  P. Plotsky,et al.  Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. , 2002, Brain research. Brain research protocols.

[15]  Qiang Zhang,et al.  In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. , 2005, Biological & pharmaceutical bulletin.

[16]  Amiram Goldblum,et al.  Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[17]  S M Gruner,et al.  Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. , 1998, Biochimica et biophysica acta.

[18]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[19]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[20]  D. Peer,et al.  Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models , 2004, Cancer Research.

[21]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[22]  Y. Barenholz,et al.  Development of liposomal anthracyclines: from basics to clinical applications. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[23]  A. Krishnan,et al.  Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. , 2008, Biochemical pharmacology.

[24]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[25]  M. Bally,et al.  Preparation, characterization, and biological analysis of liposomal formulations of vincristine. , 2005, Methods in enzymology.

[26]  P. Cullis,et al.  Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. , 1993, Biochimica et biophysica acta.

[27]  M. Mabrouk,et al.  Liquid chromatographic determination of fluoxetine. , 2002, Journal of pharmaceutical and biomedical analysis.

[28]  Uchiyama,et al.  The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. , 1999, Advanced drug delivery reviews.

[29]  D. Peer,et al.  Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. , 2009, Cancer letters.

[30]  M. Johnston,et al.  Influence of Drug-to-Lipid Ratio on Drug Release Properties and Liposome Integrity in Liposomal Doxorubicin Formulations , 2008 .

[31]  T. Skovsgaard,et al.  Cellular resistance to anthracyclines. , 1996, General pharmacology.

[32]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[33]  G. E. El Maghraby,et al.  Drug interaction and location in liposomes: correlation with polar surface areas. , 2005, International journal of pharmaceutics.

[34]  F. Penin,et al.  Highly efficient over-production in E. coli of YvcC, a multidrug-like ATP-binding cassette transporter from Bacillus subtilis. , 2002, Biochimica et biophysica acta.

[35]  R. Schubert,et al.  Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. , 2006, Biochimica et biophysica acta.

[36]  C. Logothetis,et al.  Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. , 1995, The Journal of urology.

[37]  M. Bally,et al.  Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol) , 2002, Bioscience reports.

[38]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[39]  Čeh,et al.  A Rigorous Theory of Remote Loading of Drugs into Liposomes: Transmembrane Potential and Induced pH-Gradient Loading and Leakage of Liposomes , 1997, Journal of colloid and interface science.

[40]  L. Mayer,et al.  Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. , 2010, Methods in molecular biology.

[41]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[42]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[43]  Y. Hui,et al.  Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs. , 2007, Journal of pharmacological and toxicological methods.

[44]  F. Cainelli,et al.  Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma , 2009, Biologics : targets & therapy.

[45]  S. Fabris,et al.  Interaction of fluoxetine with phosphatidylcholine liposomes. , 2005, Biophysical chemistry.

[46]  F. Szoka,et al.  Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. , 1980, Biochimica et biophysica acta.

[47]  Mathias Winterhalter,et al.  Stealth® liposomes: from theory to product , 1997 .

[48]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[49]  M. Ranson,et al.  Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. , 2001, Critical reviews in oncology/hematology.

[50]  M. Bally,et al.  The liposomal formulation of doxorubicin. , 2005, Methods in enzymology.